SLAYBACK PHARMA

VIVIMUSTA

Manufacturer:

SLAYBACK PHARMA

Vivimusta HCPCS:

J9056

HCPCS Code Descriptor:

Injection, bendamustine hydrochloride (vivimusta), 1 mg

Category:

J Code

Vivimusta NDCs:

71225-0120-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Vivimusta:

VIVIMUSTA is a Oncology drug manufactured by SLAYBACK PHARMA and administered via the Intravenous route of administration. The J Code: J9056 is aligned to the drug VIVIMUSTA.

VIVIMUSTA is a chemotherapy cancer medication that belongs to the class of drugs known as alkylating antineoplastic agent. This medication attaches to the alkyl group in the cells DNA slowing down and stopping the growth of the cancer cells. VIVIMUSTA is manufactured by Slayback pharmaceuticals and is aligned to the HCPCS code J9056.

ACCESS PRICING AND MORE BY REGISTERING

J9056 Added Date:

July 1, 2023

J9056 Effective Date:

July 1, 2023

J9056 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Vivimusta billing and coding information.
Our team did not identify a source for Vivimusta patient assistance information. Please reach out to our team if you feel that this is a mistake.
VIVIMUSTA prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for VIVIMUSTA. Please check back in a few weeks.